Angela Yee-Moon Wang

List of Publications by Year
in descending order

Version: 2024-02-01

130 papers	11,461 citations	46984 47 h-index	29127 104 g-index
164 all docs	164 docs citations	164 times ranked	11752 citing authors

#	Article	IF	Citations
1	Chronic kidney disease: global dimension and perspectives. Lancet, The, 2013, 382, 260-272.	6.3	3,135
2	KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. American Journal of Kidney Diseases, 2020, 76, S1-S107.	2.1	829
3	Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney International, 2013, 84, 1096-1107.	2.6	513
4	Cardiac Valve Calcification as an Important Predictor for All-Cause Mortality and Cardiovascular Mortality in Long-Term Peritoneal Dialysis Patients: A Prospective Study. Journal of the American Society of Nephrology: JASN, 2003, 14, 159-168.	3.0	355
5	Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2005, 20, 1676-1685.	0.4	274
6	Inflammation, Residual Kidney Function, and Cardiac Hypertrophy Are Interrelated and Combine Adversely to Enhance Mortality and Cardiovascular Death Risk of Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 2186-2194.	3.0	237
7	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	2.6	235
8	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
9	Effect of Paricalcitol on Left Ventricular Mass and Function in CKDâ€"The OPERA Trial. Journal of the American Society of Nephrology: JASN, 2014, 25, 175-186.	3.0	214
10	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	2.6	198
11	Evaluation of handgrip strength as a nutritional marker and prognostic indicator in peritoneal dialysis patients. American Journal of Clinical Nutrition, 2005, 81, 79-86.	2.2	172
12	Use of Cardiac Biomarkers in End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 1643-1652.	3.0	172
13	Is a Single Time Point C-Reactive Protein Predictive of Outcome in Peritoneal Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2003, 14, 1871-1879.	3.0	168
14	A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney International, 2002, 62, 639-647.	2.6	166
15	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	1.1	159
16	N-Terminal Pro-Brain Natriuretic Peptide: An Independent Risk Predictor of Cardiovascular Congestion, Mortality, and Adverse Cardiovascular Outcomes in Chronic Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2007, 18, 321-330.	3.0	136
17	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	2.6	135
18	Sudden Cardiac Death in End-Stage Renal Disease Patients. Hypertension, 2010, 56, 210-216.	1.3	131

#	Article	IF	Citations
19	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, l5873.	2.4	131
20	Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. American Journal of Clinical Nutrition, 2008, 87, 1631-1638.	2.2	128
21	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	2.6	126
22	Predicting timing of clinical outcomes in patientsÂwith chronic kidney disease and severely decreased glomerular filtration rate. Kidney International, 2018, 93, 1442-1451.	2.6	124
23	Independent Effects of Residual Renal Function and Dialysis Adequacy on Actual Dietary Protein, Calorie, and Other Nutrient Intake in Patients on Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 2450-2457.	3.0	122
24	Resting Energy Expenditure and Subsequent Mortality Risk in Peritoneal Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2004, 15, 3134-3143.	3.0	112
25	Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrology Dialysis Transplantation, 2005, 20, 396-403.	0.4	112
26	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	2.6	103
27	The impact of CKD identification in large countries: the burden of illness. Nephrology Dialysis Transplantation, 2012, 27, iii32-iii38.	0.4	101
28	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 74-83.	2.2	101
29	Feasibility of Resuming Peritoneal Dialysis after Severe Peritonitis and Tenckhoff Catheter Removal. Journal of the American Society of Nephrology: JASN, 2002, 13, 1040-1045.	3.0	101
30	Impact of Dialysis Adequacy on the Mortality and Morbidity of Anuric Chinese Patients Receiving Continuous Ambulatory Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2001, 12, 355-360.	3.0	93
31	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Diseases, 2020, 75, 404-412.	2.1	92
32	Chronic Inflammation in Peritoneal Dialysis: The Search for the Holy Grail?. Peritoneal Dialysis International, 2004, 24, 327-339.	1.1	90
33	Cardiac Valvular Calcification as a Marker of Atherosclerosis and Arterial Calcification in End-stage Renal Disease. Archives of Internal Medicine, 2005, 165, 327.	4.3	86
34	Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?. American Journal of Kidney Diseases, 2004, 43, 712-720.	2.1	84
35	An international Delphi survey helped develop consensus-based core outcome domains for trialsÂin peritoneal dialysis. Kidney International, 2019, 96, 699-710.	2.6	73
36	Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. American Journal of Clinical Nutrition, 2003, 77, 834-841.	2.2	72

#	Article	IF	Citations
37	Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: A prospective, randomized, controlled, multicenter study. American Journal of Kidney Diseases, 2002, 40, 373-380.	2.1	70
38	Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from aÂKidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2018, 93, 1281-1292.	2.6	69
39	Circulating soluble vascular cell adhesion molecule 1: Relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. American Journal of Kidney Diseases, 2005, 45, 715-729.	2.1	68
40	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	2.2	66
41	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 315-325.	2.1	62
42	Longitudinal Changes of Cardiac Structure and Function in CKD (CASCADE Study). Journal of the American Society of Nephrology: JASN, 2014, 25, 1599-1608.	3.0	61
43	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	2.6	60
44	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€"Children and Adolescents (SONG-KIDS) consensus workshops. Kidney International, 2020, 98, 553-565.	2.6	58
45	Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. American Journal of Clinical Nutrition, 2002, 76, 569-576.	2.2	56
46	Heart Failure in Long-Term Peritoneal Dialysis Patients: A 4-Year Prospective Analysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 805-812.	2.2	52
47	Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine, 2020, 27, 100552.	3.2	50
48	The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease. , 2021, 31, 116-120.e1.		49
49	Prognostic Value of Cardiac Troponin T Is Independent of Inflammation, Residual Renal Function, and Cardiac Hypertrophy and Dysfunction in Peritoneal Dialysis Patients. Clinical Chemistry, 2007, 53, 882-889.	1.5	48
50	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrology Dialysis Transplantation, 2020, 35, 1949-1958.	0.4	46
51	Consequences of Chronic Inflammation in Peritoneal Dialysis. Seminars in Nephrology, 2011, 31, 159-171.	0.6	40
52	Diagnostic potential of serum biomarkers for left ventricular abnormalities in chronic peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 1962-1969.	0.4	39
53	Cefazolin plus Ceftazidime versus Imipenem / Cilastatin Monotherapy for Treatment of Capd Peritonitis â€" a Randomized Controlled Trial. Peritoneal Dialysis International, 2004, 24, 440-446.	1.1	37
54	Heart Failure With Preserved or Reduced Ejection Fraction in Patients Treated With Peritoneal Dialysis. American Journal of Kidney Diseases, 2013, 61, 975-983.	2.1	37

#	Article	IF	Citations
55	Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases. Kidney International, 2001, 59, 2309.	2.6	37
56	Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?. American Journal of Kidney Diseases, 2004, 43, 712-20.	2.1	36
57	Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients. Kidney International, 2003, 63, 1899-1907.	2.6	34
58	Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. Nephrology Dialysis Transplantation, 2009, 24, 3826-3833.	0.4	34
59	Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. Peritoneal Dialysis International, 2022, 42, 8-24.	1.1	33
60	Increased Circulating Inflammatory Proteins Predict a Worse Prognosis with Valvular Calcification in End-Stage Renal Disease: A Prospective Cohort Study. American Journal of Nephrology, 2008, 28, 647-653.	1.4	31
61	Current Perspectives on Diagnosis of Heart Failure in Long-term Dialysis Patients. American Journal of Kidney Diseases, 2011, 57, 308-319.	2.1	30
62	Precision Medicine for Nutritional Management in End-Stage Kidney Disease and Transition to Dialysis. Seminars in Nephrology, 2018, 38, 383-396.	0.6	30
63	2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Diseaseâ€“Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. Kidney International Reports, 2019, 4, 1523-1537.	0.4	29
64	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysisâ€”International Results from PDOPPS. Kidney International Reports, 2021, 6, 313-324.	0.4	29
65	Vascular and Other Tissue Calcification in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2009, 29, 9-14.	1.1	27
66	International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). Peritoneal Dialysis International, 2020, 40, 310-319.	1.1	27
67	Nutrient Intake During Peritoneal Dialysis at the Prince of Wales Hospital in Hong Kong. American Journal of Kidney Diseases, 2007, 49, 682-692.	2.1	26
68	Clinical Utility of Natriuretic Peptides in Dialysis Patients. Seminars in Dialysis, 2012, 25, 326-333.	0.7	26
69	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 100, 35-48.	2.6	26
70	The Diagnostic Utility of Cardiac Biomarkers in Dialysis Patients. Seminars in Dialysis, 2012, 25, 388-396.	0.7	25
71	Calcium Balance and Negative Impact of Calcium Load in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2014, 34, 345-352.	1.1	25
72	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. BMJ Open, 2021, 11, e047245.	0.8	25

#	Article	IF	Citations
73	Skin Autofluorescence Associates With Vascular Calcification in Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1784-1790.	1.1	24
74	Dietary Fiber Intake, Myocardial Injury, andÂMajor Adverse Cardiovascular Events Among End-Stage Kidney Disease Patients: A Prospective Cohort Study. Kidney International Reports, 2019, 4, 814-823.	0.4	24
75	Hemodialysis Use and Practice Patterns: An International Survey Study. American Journal of Kidney Diseases, 2021, 77, 326-335.e1.	2.1	24
76	Differential Associations of Traditional and Non-Traditional Risk Factors with Carotid Intima-Media Thickening and Plaque in Peritoneal Dialysis Patients. American Journal of Nephrology, 2007, 27, 458-465.	1.4	23
77	Volume management as a key dimension of a high-quality PD prescription. Peritoneal Dialysis International, 2020, 40, 282-292.	1.1	23
78	Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 38-52.	2.2	23
79	Vascular and Valvular Calcification in Chronic Peritoneal Dialysis Patients. International Journal of Nephrology, 2011, 2011, 1-9.	0.7	22
80	Is Valvular Calcification a Part of the Missing Link between Residual Kidney Function and Cardiac Hypertrophy in Peritoneal Dialysis Patients?. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1629-1636.	2.2	20
81	Prognostic Value of Plasma Myeloperoxidase in ESRD Patients. American Journal of Kidney Diseases, 2010, 56, 937-946.	2.1	20
82	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	2.6	20
83	Energy intake and expenditure profile in chronic peritoneal dialysis patients complicated with circulatory congestion. American Journal of Clinical Nutrition, 2009, 90, 1179-1184.	2.2	19
84	The Impact of Increasing the Daytime Dialysis Exchange Frequency on Peritoneal Dialysis Adequacy and Nutritional Status of Chinese Anuric Patients. Peritoneal Dialysis International, 2002, 22, 197-203.	1.1	18
85	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 79-87.	2.2	18
86	Severe acute respiratory syndrome in a hemodialysis patient. American Journal of Kidney Diseases, 2003, 42, 1069-1074.	2.1	17
87	Association of dietary patterns with serum phosphorus in maintenance haemodialysis patients: a cross-sectional study. Scientific Reports, 2020, 10, 12278.	1.6	17
88	Handgrip strength, but not other nutrition parameters, predicts circulatory congestion in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 3372-3379.	0.4	16
89	Sleep-Disordered Breathing and Resistant Hypertension. Seminars in Nephrology, 2014, 34, 520-531.	0.6	16
90	Cardiovascular risk in diabetic end-stage renal disease patients. Journal of Diabetes, 2011, 3, 119-131.	0.8	15

#	Article	IF	Citations
91	Treatment of Heart Failure in Long-term Dialysis Patients: A Reappraisal. American Journal of Kidney Diseases, 2011, 57, 760-772.	2.1	14
92	Plasma sodium and subclinical left atrial enlargement in chronic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 2319-2328.	0.4	14
93	Patient and caregiver perspectives on burnout in peritoneal dialysis. Peritoneal Dialysis International, 2021, 41, 484-493.	1.1	14
94	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.4	14
95	Physical Activity and Health in Chronic Kidney Disease. Contributions To Nephrology, 2021, 199, 43-55.	1.1	14
96	Review Article. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: What is the evidence?. Nephrology, 2004, 9, 190-197.	0.7	12
97	Personalizing heart failure management in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2022, 37, 2055-2062.	0.4	11
98	The John F. Maher Award Recipient Lecture 2006. The "heart" of peritoneal dialysis: residual renal function. Peritoneal Dialysis International, 2007, 27, 116-24.	1.1	11
99	The "heart" of peritoneal dialysis. Peritoneal Dialysis International, 2007, 27 Suppl 2, S228-32.	1.1	11
100	Vascular and other tissue calcification in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29 Suppl 2, S9-S14.	1.1	11
101	Cardiovascular risk factors in peritoneal dialysis patients revisited. Peritoneal Dialysis International, 2007, 27 Suppl 2, S223-7.	1.1	10
102	Preserving Residual Kidney Function in Hemodialysis Patientsâ€"Back in the Spotlight. Journal of the American Society of Nephrology: JASN, 2016, 27, 3504-3507.	3.0	9
103	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. Peritoneal Dialysis International, 2022, 42, 279-287.	1.1	9
104	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. Nephrology Dialysis Transplantation, 2021, 37, 159-167.	0.4	9
105	Energy Intake and Energy Expenditure Profiles in Peritoneal Dialysis Patients. , 2011, 21, 31-34.		8
106	Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrology Dialysis Transplantation, 2019, 34, iii36-iii44.	0.4	8
107	Vitamin B12 and chronic kidney disease. Vitamins and Hormones, 2022, 119, 325-353.	0.7	8
108	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	2.6	7

#	Article	IF	Citations
109	Assisted peritoneal dialysis performed by caregivers and its association with patient outcomes. Peritoneal Dialysis International, 2022, 42, 602-614.	1.1	7
110	Uraemic tumoural calcinosis. Nephrology Dialysis Transplantation, 2004, 19, 505-506.	0.4	6
111	Renal Function and Bisphosphonate Safety. Journal of Bone and Mineral Research, 2008, 23, 453-454.	3.1	5
112	RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 retrospective cohort study. BMJ Open, 2020, 10, e034103.	0.8	5
113	Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 1761-1769.	0.4	5
114	The World Kidney Recipes: Teaming up to Empower Patients, Care-Partners, Dietitians, and Chefs With Culinary Creativity and Multicultural Diversity in Renal Nutrition and Dietetics. , 2021, 31, 545-549.		5
115	Global Kidney Nutrition Care and Health Literacy: Overcoming the Disparities in Renal Nutrition Service Capacity and Education. , 2022, 32, 127-130.		5
116	A confused uraemic woman. Lancet, The, 2001, 357, 278.	6.3	4
117	Early Versus Late Initiation of Dialysis and Nutrition: Does a Transition Mean a Change in Dietary Protein Intake?. , 2013, 23, 228-232.		4
118	Nutrition and Obesity Impacts on Kidney Health. Contributions To Nephrology, 2021, 199, 1-19.	1.1	4
119	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1817-1825.	1.4	4
120	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	0.9	4
121	Does Vitamin B12 Delay CKD Progression?. American Journal of Kidney Diseases, 2020, 75, 317-319.	2.1	3
122	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.4	2
123	Long-Term Effects of Sevelamer on Vascular Calcification, Arterial Stiffness, and Calcification Propensity in Patients Receiving Peritoneal Dialysis: The Randomized Pilot SERENE (Sevelamer on) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	1
124	Selective internal radiation therapy by yttrium-90 microspheres for hepatocellular carcinoma after renal transplantation. Clinical Transplantation, 2001, 15, 284-288.	0.8	1
125	Cardiovascular Disease in End-stage Renal Disease. Hong Kong Journal of Nephrology, 2006, 8, 10-16.	0.0	1
126	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Nephrology and Dialysis, 2020, 22, 152-167.	0.2	1

#	Article	IF	Citations
127	Anasarca secondary to problems in three organs: one man with three diseases?. Nephrology Dialysis Transplantation, 2004, 19, 1651-1653.	0.4	0
128	Reply to C Fourtounas and JG Vlachojannis. American Journal of Clinical Nutrition, 2009, 89, 436-438.	2.2	0
129	Dialysis modality and survival in ESRDâ€"is the debate over?. Nature Reviews Nephrology, 2011, 7, 612-614.	4.1	0
130	Comparing survival between home hemodialysis and peritoneal dialysis â€“ is the controversy over?. Nephrology Dialysis Transplantation, 2022, , .	0.4	0